CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 42 enrolled
Drug / intervention
Vaporization of Cannabisdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01555983
NCT01555983Phase 3Completed
CompareCT.gov

The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury

Barth Wilsey·interventional·Posted Mar 16, 2012·Updated Apr 18, 2017

In Brief

A Phase 3 clinical trial evaluating Vaporization of Cannabis for Spinal Cord Injuries and Spinal Cord Diseases. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries, Spinal Cord Diseases
CountriesUnited States
CollaboratorsVA Northern California Health Care System, University of California, San Diego, National Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 16, 2012
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.3 years ago

Interventions

Vaporization of Cannabisdrug

Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC